In Labs reserves 35% of net issue for bids above ₹2 lakh

In Labs reserves not less than 35% of its 33,58,400-share net issue for Individual Bidders, but access requires an application above ₹2 lakh and for more than two lots. The stated allocation is at least 11,80,800 equity shares, making the individual category distinct from a small-ticket retail-style application.

Why does In Labs reserve 35% for bids above ₹2 lakh?

In Labs assigns at least 35% of the net issue to Individual Bidders, subject to valid bids being received at or above the issue price. The issue structure identifies resident individuals, Hindu Undivided Families, or HUFs, acting through their karta, and eligible non-resident Indians as the applicants who can use this category.

The defining requirement is the application threshold. In Labs states that eligible Individual Bidders must apply for equity shares so that the bid amount is above two lots and the minimum application size is above ₹2 lakh. The minimum-bid-size row repeats that the individual bid must cover two lots and be above ₹2 lakh, so an applicant must meet both the lot and monetary conditions.

The 35% reservation applies to the net issue rather than the total issue. In Labs offers up to 35,36,000 equity shares of face value ₹10 each, including a market-maker reservation of up to 1,77,600 shares. Removing that reservation leaves a net issue of up to 33,58,400 shares, which represents 25.63% of post-issue equity share capital, compared with 26.99% for the full issue.

The market-maker reservation accounts for 5.02% of the issue size and receives firm allotment. In Labs says the market-maker portion is at least 5% of the issue, while the individual allocation is calculated from shares remaining in the net issue. This separation is why the 35% individual allocation cannot be measured against all 35,36,000 shares in the offer.

How are In Labs shares divided among bidder categories?

In Labs has disclosed at least 11,80,800 shares for Individual Bidders, at least 5,12,000 for Non-Institutional Bidders and up to 16,65,600 for Qualified Institutional Buyers, or QIBs. The three categories together equal the 33,58,400-share net issue, assuming full subscription as stated in the issue structure.

The individual allocation is 20 percentage points larger than the minimum non-institutional allocation. It is not, however, an allocation for every individual regardless of application value: In Labs limits the Individual Bidders category to bids above ₹2 lakh and more than two lots.

QIB is a regulatory category that includes specified public financial institutions, scheduled commercial banks, mutual funds, eligible foreign portfolio investors, venture capital funds, alternative investment funds and other entities listed in the offer document. In Labs may allocate up to 60% of the QIB portion to anchor investors on a discretionary basis, subject to the stated regulatory conditions. No comparable anchor allocation is specified for Individual Bidders.

How does the individual portion differ from non-institutional bids?

In Labs reserves at least 15% of the net issue for Non-Institutional Bidders, against at least 35% for Individual Bidders. The non-institutional portion is split into two application-size segments: one-third for applications above two lots up to ₹10 lakh, and two-thirds for applications above ₹10 lakh.

If one non-institutional sub-category is undersubscribed, In Labs may allocate its unallocated shares to applicants in the other sub-category, subject to applicable rules. This internal split differs from the Individual Bidders portion, for which the document states a single minimum application condition of above ₹2 lakh and more than two lots.

The basis of allotment also differs by category. In Labs states that each individual allotment will not be less than the minimum bid lot, subject to share availability in the individual portion, and that remaining shares, if any, will be allotted proportionately. For non-institutional applicants, each category must receive at least the relevant minimum application size, subject to availability, with the balance allotted proportionately.

Under-subscription can affect final availability. In Labs says under-subscription in a category other than the QIB portion may be met through spill-over from another category or combination of categories, at the company’s discretion in consultation with the book running lead manager and designated stock exchange. QIB under-subscription cannot be met through spill-over from other categories.

What payment and holding rules apply to In Labs bids?

In Labs requires Individual Bidders to submit bids through the Application Supported by Blocked Amount, or ASBA, process through banks or by using a Unified Payments Interface, or UPI, identification method. Under ASBA, the application amount is blocked in the investor’s specified bank account while the bid is processed rather than paid immediately to the issuer.

The offer document cites a Securities and Exchange Board of India, or SEBI, circular dated April 5, 2022 that requires individual investors using applications up to ₹5 lakh in initial public offerings to use the UPI mechanism. It also says that non-institutional investors bidding above ₹2 lakh and up to ₹5 lakh through UPI must provide their UPI identification in the bid-cum-application form when using the specified channels.

All allotted equity shares will be issued in dematerialised form. In Labs states that an application without depository-account details, including the depository participant identification number and beneficiary account number, will be incomplete and rejected. Applications without a Permanent Account Number, except for specified exempt applicants, are also liable to rejection.

In Labs states that application money must be blocked before ASBA applications are processed. Where ASBA or UPI-blocked amounts are not unblocked within more than two working days from the issue closing date, the bidder is entitled to compensation in accordance with applicable law. The book running lead manager may identify the intermediary or entity responsible for the delay.

What remains unclear in the In Labs individual-bid terms?

In Labs contains a wording inconsistency in the Individual Bidders column. Its eligibility and minimum-bid provisions say that the application must be above two lots and above ₹2 lakh, while the maximum-bid row says the application should not exceed two lots. The source does not reconcile these conflicting references.

The document’s more detailed eligibility description supports the above-two-lot threshold because it specifically says resident individuals, HUFs and eligible non-resident Indians must apply for shares with a bid amount above two lots and above ₹2 lakh. The stated allocation rule also refers to Individual Bidders who apply for the minimum application size, rather than setting out a lower-value retail application.

In Labs also says that a price-band revision would extend the bid or issue period by at least three additional working days, subject to the total period not exceeding 10 working days. Such a revision would change the application timetable, but the document does not say that it would automatically change the 35% allocation, the ₹2 lakh threshold or the lot requirement.

Conclusion

In Labs has structured at least 11,80,800 shares, or 35% of its 33,58,400-share net issue, for Individual Bidders whose applications exceed ₹2 lakh and more than two lots. The allocation is therefore a defined individual-investor category with a stated minimum application threshold, not a general small-ticket retail bucket.

The key item to watch is whether In Labs resolves the conflicting maximum-bid language before the final offer process. The disclosed plan also provides for compulsory market making on the BSE SME Platform for at least three years from listing, while final listing and trading remain subject to the required approvals.